1. Secukinumab is effective in treatment of moderate‐to‐severe plaque psoriasis: real‐life effectiveness and safety from the PROSPECT study. (17th October 2019) Authors: Thaçi, D.; Körber, A.; von Kiedrowski, R.; Bachhuber, T.; Melzer, N.; Kasparek, T.; Duetting, E.; Kraehn‐Senftleben, G.; Amon, U.; Augustin, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 2(2020) Page Start: 310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. (22nd November 2017) Authors: Körber, A.; Thaçi, D.; von Kiedrowski, R.; Bachhuber, T.; Melzer, N.; Kasparek, T.; Kraehn‐Senftleben, G.; Amon, U.; Augustin, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 3(2018) Page Start: 411 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗